Lung Ultrasound Improves Outcome Prediction over Clinical Judgment in COVID-19 Patients Evaluated in the Emergency Department

Paolo Bima, Emanuele Pivetta, Denise Baricocchi, Jacopo Davide Giamello, Francesca Risi, Matteo Vesan, Michela Chiarlo, Giuliano De Stefano, Enrico Ferreri, Giuseppe Lauria, Stefano Podio, Peiman Nazerian, Franco Aprà, Enrico Lupia, Fulvio Morello, and on behalf of the CODED Study Investigators

1. Background

Pandemic waves of SARS-CoV-2 infection lead to Emergency Department (ED) overcrowding, hospital admission peaks for COVID-19 and shortages in hospital beds for non-COVID-19 patients [1–3]. The standardized identification of SARS-CoV-2 positive patients not requiring hospital admission is therefore a clinical and system need. Ideal
candidates for ED discharge and home treatment are individuals with mild disease and a sufficiently low risk of adverse events such as respiratory failure and death. However, the development of standardized ED disposition rules for COVID-19 is challenging, because balancing the assessment of current clinical severity and the risk of subsequent deterioration is demanding [4].

Prognostication tools or scores evaluating key clinical variables may assist ED disposition decision, as already established for community-acquired pneumonia [5,6]. For instance, the HOME-CoV (HCR), developed and validated in the ED, dichotomically identifies patients at a low risk of adverse events based on clinical presentation, course, comorbidities and living context. The 4C mortality score (4CMS), instead, developed on large inpatient cohorts, provides a graded risk-stratification (score 0 to 21) based on clinical presentation, comorbidities and selected blood test results [7–11]. However, the superiority of standardized rules/scores over subjective clinical judgment has not been shown, and the potential effects of these tools on hospital admission rates are largely unknown.

In ED facilities, lung ultrasonography (LUS) has emerged as a key point-of-care or portable tool for assessment of COVID-19 patients, either suspected or confirmed [12–14]. At the patient’s bedside, LUS can easily and rapidly detect SARS-CoV-2-related interstitial lung involvement, and in COVID-19 patients, LUS findings have prognostic value, with extensive/severe patterns predicting an increased risk of ARDS, mechanical ventilation and death [15–17]. LUS could therefore provide valuable data to complement clinical judgment and to inform disposition decisions. The present study tested the hypothesis that LUS, alone or integrated with standardized clinical tools, may improve the risk stratification and disposition decision for COVID-19 patients evaluated in the ED, compared to clinical judgment alone.

2. Methods

2.1. Design and Setting of the Study

This was a multicenter prospective observational cohort study performed on COVID-19 patients from six EDs, in three Italian regions. Two are located in large tertiary university hospitals (Molinette Hospital, Turin and Careggi Hospital, Florence), two in tertiary non-university hospitals (Santa Croce e Carle Hospital, Cuneo; San Giovanni Bosco Hospital, Turin) and two in secondary non-university hospitals (Maria Vittoria Hospitals, Turin; Parini Hospital, Aosta). Enrolment was conducted from 10 October 2020 to 11 January 2021. The study was registered on clinicaltrials.org (NCT04629183) and approved by the local ethics committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino, A.O. Ordine Mauriziano, A.S.L. Città di Torino, 0031189/24 March 2020 and 0009810/29 January 2021). The general patient characteristics and validation of the 4CMS in this cohort have been previously described [11].

2.2. Characteristics of Participants

Consecutive ED outpatients were enrolled in the presence of (1) a positive molecular test for SARS-CoV-2 obtained within 14 days prior to the index visit; (2) COVID-19 symptoms leading to an ED visit and dating <14 days; (3) discharge disposition from the ED, owing to physician’s decision or patient’s own will. Exclusion criteria were age <18 years, refusal to give consent, nursing care residence, long-term oxygen therapy and previous ED access for suspected or confirmed COVID-19. Only patients subjected to LUS were analyzed in the present study.

2.3. Interventions during the Index Visit

The workup of eligible patients was independent of study participation. ED physicians operated in compliance with national guidelines from the Ministry of Health (MOH, Circ. 0024970-30 November 2020), but ED disposition decisions were based on subjective clinical
judgment and did not follow a standardized protocol. All diagnostic results were available to treating physicians during the index visit. Attending physicians prospectively recorded demographic, clinical and LUS data on a standardized case report form.

2.4. Lung Ultrasonography

Attending physicians were all trained in LUS of COVID-19 patients [18]. If logistically feasible, they performed LUS as a point-of-care exam during the index visit. In order to expedite evaluation and reporting, they were instructed to perform a minimum standardized assessment using either a curvilinear transducer (5–3 MHz, Esaote Mylab5 or Mylab7, Genova, Italy) or a handheld device (Butterfly iQ; Butterfly Network Inc., Guilford, CT, USA) with a lung preset (3 MHz). Representative scans were registered for random quality control, but systematic recording and independent adjudication were not performed.

The thorax was scanned thoroughly for presence of interstitial syndrome and lung consolidations, as previously described [12]. A modified semi-quantitative LUS score was calculated as the score for B-lines (indicating interstitial lung inflammation) + score for lung consolidations. The score for B-lines was calculated as the number of lung areas with \( \geq 3 \) B-lines, using 8 areas (4 per side, shown in Figure 1A,B). The score for lung consolidations was 0 for absence of consolidations, 3 for unilateral consolidation(s) or 6 for bilateral consolidations [19]. A lung consolidation was defined as evidence of a non-aerated lung tissue consolidation larger than 1 cm (Figure 1C) [20]. Hence, the modified LUS score ranged from 0 (absence of B-lines and consolidations) to 14 points (presence of B-lines in 8 areas plus bilateral consolidations).

![Figure 1](image-url)

**Figure 1.** Panel (A): Lung areas for the calculation of the modified LUS score. 1: right upper antero-lateral area; 2: right lower antero-lateral area; 3: left upper antero-lateral area; 4: left lower antero-lateral area; 5: right upper posterior area; 6: right lower posterior area; 7: left upper posterior area; 8: left lower posterior area. Panel (B): representative LUS image showing B-lines. Panel (C): representative LUS image showing a lung consolidation.

2.5. Clinical Score Calculation

The HCR, described in Supplementary Table S1, was calculated according to Duillet et al., excluding the variable “clinically significant worsening within the last 24 h”, which lacked a standard definition [7]. The 4CMS, described in Supplementary Table S2, was calculated according to Knight et al. [8]. If urea was not available, we used corresponding creatinine cutoff levels established on a training ED cohort of 832 patients subjected to a simultaneous urea/creatinine assay, as previously detailed [11].
2.6. Outcomes

The primary outcome was as a composite of all-cause death or hospital admission occurring within 30 days from the index ED visit. The secondary outcome was a composite of all-cause death or the need for non-invasive ventilation, high-flow nasal cannula or intensive care unit admission, occurring within 30 days.

For outcome retrieval, we performed a hospital database search, acquisition of medical charts and a structured phone interview conducted by a trained researcher. Two independent and expert physicians, blinded to the index ED visit data, made final case adjudication. In case of discordance, a third independent evaluation was planned.

2.7. Study Power

The present study was powered to test the null hypothesis that a binary discharge rule based on LUS identifies patient groups with a 10% difference in primary outcome occurrence (5% in the LUS negative group and 15% in the LUS positive group). This estimate was based on previous data, where mortality in COVID-19 patients potentially suitable for ED discharge was 1.2% for low-risk patients and 9.9% for intermediate risk patients, according to 4CMS [8]. Using an alpha error of 5% and a power of 90%, we estimated that at least 300 patients needed to be included.

2.8. Data Analysis

We expressed continuous variables as the mean and standard deviation (SD) or median and interquartile range (IQR), as appropriate. Categorical variables were expressed as absolute numbers and percentages. We assessed prognostic discrimination for each outcome using the C-indexes, which were compared using the DeLong’s test for paired curves, and standard performance measures (sensitivity, specificity) [21]. The best cut-off for the LUS score was the one associated with the maximum product of sensitivity and specificity [22]. Sensitivity and specificity values of different strategies were compared using the binomial exact test (paired samples) [23]. Proportions of patients ruled-out with different strategies were compared using a z test for partially overlapping samples [24]. Overall goodness of fit for LUS results was assessed using the Brier score [25] and model calibration with Cox’s intercept and slope [26].

The survival analysis was carried out with the Kaplan–Meier estimator, using the log-rank test for comparison of the curves and Cox regression. *p*-values were considered statistically significant if <0.05. The statistical analysis was performed with R (v3.6.4).

3. Results

3.1. Patient Characteristics and Outcomes

Within 521 patients with enrolment criteria, 393 with available LUS data were further analyzed. The mean age was 51 ± 16 years. Two-hundred patients (50.9%) were male, and 79 (20.1%) had at least one comorbidity. One-hundred twenty patients (30.5%) were HCR positive, and 30 (7.6%) were at high risk, according to 4CMS. The overlap of HCR and 4CMS classification is shown in Supplementary Figure S2A.

The primary outcome occurred in 19 HCR-positive and in 8 high-risk patients (Supplementary Table S3). Within 30 days, the primary outcome was reached in 35 (8.9%) patients and the secondary outcome in 14 (3.6%). Fourteen (3.6%) needed NIV/HFNC, one (0.3%) was admitted to intensive care and two (0.5%) patients died.

3.2. LUS Results

LUS-defined lung involvement was absent (score = 0) in 234 (59.5%) patients, interstitial involvement in one lung area (score = 1) in 40 (10.2%) and in multiple lung areas or any consolidation (score ≥ 2) were present in 119 (30.3%, of whom 10 (8.4%) had ≥1 lung consolidation). As shown in Figure 2 and in Supplementary Table S4, increased LUS-defined lung involvement was associated with worse clinical outcomes. The calibration plots for LUS-based outcome prognostication are shown in Supplementary Figure S1. The Brier
score, Cox’s intercept and slope for the primary and secondary outcome were respectively 0.08/0/1, and 0.03/0/1.04, indicating good overall performance and modest calibration. The cross-tabulation of LUS and clinical scores is represented in Supplementary Figure S2B.

Figure 2. Patient number and primary and secondary outcome occurrence in patients stratified by LUS results.

3.3. Outcome Prediction

The prognostic curves of clinical scores and LUS for outcome prediction are shown in Figure 3. For the primary outcome, C-index values were 0.63 (0.54–0.72) for HCR, 0.79 (0.73–0.86) for 4CMS \( p < 0.001 \) vs. HCR) and 0.76 (95%CI 0.68–0.84, \( p = 0.04 \) vs. HCR) for LUS. For the secondary outcome, C-index values were 0.64 (95%CI 0.50–0.77) for HCR, 0.75 (95%CI 0.66–0.85) for 4CMS \( p = 0.09 \) vs. HCR), and 0.8 (95% 0.68–0.92) for LUS \( p = 0.11 \) vs. HCR). Logistic models including each diagnostic tool along with symptom onset showed similar results (Supplementary Table S4).

Figure 3. ROC curve analysis for prediction of (A) primary outcome and (B) secondary outcome. TP: True Positive; TN: True Negative; FP: False Positive; FN: False Negative.
The sensitivity and specificity values of the LUS for outcome prediction are shown in Figure 3. The optimal LUS cut-off was 2 for both outcomes. A positive LUS (score ≥ 2) identified a subgroup of patients at increased outcome probability at the Kaplan–Meier estimator (log-rank test \( p \)-value < 0.001 for both outcomes, Figure 4). The hazard ratio of positive LUS adjusted for age and sex was 4.33 (95%CI 1.95–9.61) for the primary outcome and 5.75 (95%CI 1.48–22.3) for the secondary outcome.

![Figure 3. ROC curve analysis for prediction of (A) primary outcome and (B) secondary outcome. TP: True Positive; TN: True Negative; FP: False Positive; FN: False Negative.](image)

![Figure 4. Kaplan–Meier curves for the (A) primary outcome and (B) secondary outcome in patients stratified by LUS results.](image)

3.4. Comparison of LUS with Clinical Scores

We next evaluated risk stratification obtained with LUS, HCR or 4CMS alone or the integration of HCR/4CMS with LUS. Sensitivity and specificity values for outcome prediction are shown in Table 1. For both outcomes, sensitivity was highest using HCR-LUS integration (HCR positive or LUS positive).

Outcome occurrence rates in patients satisfying different rule-out criteria are shown in Table 2. In LUS-negative patients, the primary and secondary outcome occurrence rates were 3.3% and 1.1%, respectively (\( p < 0.001 \) vs. unselected). The corresponding rule-out efficiency was 69.7%. The lowest outcome occurrence rates (1.4% primary, 0.5% secondary) were observed in HCR-negative and LUS-negative patients (\( p < 0.001 \) vs. LUS negative patients), with an efficiency of 52.7%. Rule-out using an integration of 4CMS with LUS was associated with occurrence rates of 2.7% and 1.2% and an efficiency of 65.9%.
Table 1. Outcome prediction performance for the primary and secondary outcome.

| Primary Outcome | TP  | TN   | FP  | FN  | Sensitivity | p-Value * | Specificity | p-Value * |
|-----------------|-----|------|-----|-----|-------------|-----------|-------------|-----------|
| LUS positive    | 26  | 265  | 93  | 9   | 74.3%       | -         | 74%         | -         |
|                 |     |      |     |     | (59.8–88.8) |           | (69.5–78.6) |           |
| HCR positive    | 19  | 257  | 101 | 16  | 54.3%       | 0.17      | 71.8%       | 0.52      |
|                 |     |      |     |     | (37.8–70.8) |           | (69.5–76.4) |           |
| HCR positive and LUS positive | 13 | 318  | 40  | 22  | 37.1%       | <0.001    | 88.8%       | <0.001    |
|                 |     |      |     |     | (21.1–53.2) |           | (85.6–92.1) |           |
| HCR positive or LUS positive | 32 | 204  | 154 | 3   | 91.4%       | 0.03      | 57%         | <0.001    |
|                 |     |      |     |     | (82.2–100)  |           | (51.9–62.1) |           |
| High risk (4CMS ≥ 9) | 8  | 336  | 22  | 27  | 22.9%       | <0.001    | 93.9%       | <0.001    |
|                 |     |      |     |     | (8.9–36.8)  |           | (91.4–96.3) |           |
| High risk (4CMS ≥ 9) or LUS positive | 28 | 252  | 106 | 7   | 80%         | 0.5       | 70.4%       | <0.001    |
|                 |     |      |     |     | (66.7–93.3) |           | (65.7–75.1) |           |
| Secondary Outcome | TP  | TN   | FP  | FN  | Sensitivity | p-Value * | Specificity | p-Value * |
| LUS positive    | 11  | 271  | 108 | 3   | 78.6%       | -         | 71.5%       | -         |
|                 |     |      |     |     | (57.1–100)  |           | (67.0–76.0) |           |
| HCR positive    | 8   | 267  | 112 | 6   | 57.1%       | 0.45      | 70.4%       | 0.78      |
|                 |     |      |     |     | (31.2–83.1) |           | (65.9–75)  |           |
| HCR positive and LUS positive | 6  | 332  | 47  | 8   | 42.6%       | 0.06      | 87.6%       | <0.001    |
|                 |     |      |     |     | (16.9–68.8) |           | (84.3–90.9) |           |
| HCR positive or LUS positive | 13 | 206  | 173 | 1   | 92.9%       | 0.5       | 54.4%       | <0.001    |
|                 |     |      |     |     | (79.4–100)  |           | (49.3–59.4) |           |
| High risk (4CMS ≥ 9) | 2  | 351  | 28  | 12  | 14.3%       | 0.004     | 92.6%       | <0.001    |
|                 |     |      |     |     | (0–32.6%)   |           | (90.0–95.2) |           |
| High risk (4CMS ≥ 9) or LUS positive | 11 | 256  | 123 | 3   | 78.9%       | 1.0       | 67.5%       | <0.001    |
|                 |     |      |     |     | (57.1–100)  |           | (62.8–72.3) |           |

Legend. FN: False Negative; FP: False Positive; TN: True Negative; TP: True Positive. * calculated vs. LUS positive.
Table 2. Occurrence of primary and secondary outcomes in patient categories based on subjective evaluation alone (all patients), LUS, HOME-CoV (HCR), 4CMS or integration of LUS with HCR or 4CMS.

| N * | Primary Outcome | p-Value vs. All | p-Value vs. LUS | Secondary Outcome | p-Value vs. All | p-Value vs. LUS |
|-----|-----------------|-----------------|-----------------|------------------|-----------------|-----------------|
| All patients | 393 (100%) | 35 (8.9% [95%CI 6.5–12.1]) | - | - | 14 (3.6% [95%CI 2.1–5.9]) | - | - |
| LUS negative | 274 (69.7%) | 9 (3.3% [95%CI 1.4–5.1]) | <0.001 | - | 3 (1.1% [95%CI 0.4–3.2]) | <0.001 | - |
| HCR negative | 273 (69.5%) | 16 (5.9% [95%CI 3.6–9.3]) | <0.001 | 0.003 | 6 (2.2% [95%CI 0.7–3.7]) | 0.01 | 0.04 |
| HCR negative or HCR positive and LUS negative | 340 (86.5%) | 22 (6.5% [95%CI 4.3–9.6]) | <0.001 | <0.001 | 8 (2.4% [95%CI 1.2–4.6]) | <0.001 | <0.001 |
| HCR negative and LUS negative | 207 (52.7%) | 3 (1.4% [95%CI 0.5–4.2]) | <0.001 | <0.001 | 1 (0.5% [95%CI 0.02–2.7]) | 0.03 | 0.05 |
| Low/intermediate risk (4CMS ≤ 8) | 363 (92.4%) | 27 (7.4% [95%CI 5.2–10.6]) | <0.001 | <0.001 | 12 (3.3% [95%CI 1.9–5.7]) | 0.33 | <0.001 |
| Low/intermediate risk (4CMS ≤ 8) and LUS negative | 259 (65.9%) | 7 (2.7% [95%CI 1.3–5.5]) | <0.001 | 0.02 | 3 (1.2% [95%CI 0.4–3.3]) | <0.001 | 0.68 |

* The % value in brackets corresponds to the rule-out efficiency, which can be calculated as (TN + FN)/(TP + FP + TN + FN). FN: False Negative; FP: False Positive; TN: True Negative; TP: True Positive.
4. Discussion

To our knowledge, this is the first study directly evaluating LUS as a tool assisting physicians for risk assessment of COVID-19 outpatients. Results show that LUS provides an incremental prognostication capacity over clinical judgment alone and that LUS-based discharge rules may improve the safety of ED discharge dispositions.

In this study cohort recruited in the pre-vaccination era, a non-standardized discharge disposition made by treating physicians through subjective clinical judgment/gestalt was indeed associated with a substantial number of patients (1 in 11) requiring subsequent hospital admission or developing adverse clinical outcomes, including death. This finding is in line with a previous North American study reporting 8.2% readmission rate at 7 days for unvaccinated COVID-19 patients and confirms the need for improved risk-stratification of COVID-19 patients in the ED when evaluating final disposition [27].

In the present study, negative LUS, defined by interstitial involvement in no more than one lung area and the absence of lung consolidations, was indeed associated with mild clinical outcomes (3.3% and 1.1% for primary and secondary, respectively). The expected impact of this approach on hospital admissions, compared to clinical judgment alone, is moderate, with about 30% of patients requiring hospital admission. A further reduction in adverse clinical outcomes can be obtained by integrating LUS with a clinical score (either HCR or 4CMS), leading to a more substantial increase in patients requiring hospital admission in association with HCR (about 50%).

Our study has limitations. First, we conducted the study in a pre-vaccination phase. Therefore, outcome estimates would now essentially apply to unvaccinated individuals. Second, the study’s focus on discharged patients likely led to the selection of milder and less frail patients, limiting external validity for unselected ED patients. Third, LUS was not performed in all patients, but the reason for not performing LUS was not reported by the attending physicians. Fourth, although LUS has a steep learning curve and LUS was always performed by trained physicians, LUS images were not recorded and did not undergo central adjudication [28]. Fifth, conduction of the study during a pandemic peak pragmatically led to calculation of a quick semi-quantitative LUS score. The corresponding cutoff using a standard LUS score is likely about 4, but external validation is warranted [29]. Finally, our study protocol did not include blinding, since LUS was performed during the medical evaluation by attending physicians, potentially influencing clinical management and final disposition.

5. Conclusions

In unvaccinated COVID-19 patients evaluated in the ED for final disposition, LUS assessment, alone or integrated with a clinical risk score, improves outcome prognostication over clinical judgment alone. Patients with minor or absent LUS findings are at a very low risk of adverse outcomes and can be safely discharged. The systematic application of LUS for the disposition decision is expected to increase the safety of patient discharge over clinical judgment alone, while slightly increasing hospital admission rates. Confirmatory studies on contemporary cohorts comprising vaccinated patients and new SARS-CoV-2 variants are warranted.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11113032/s1, Table S1: Variables in the HOME-CoV rule, adapted from Duillet D. et al. Presence of one or more criteria corresponds to a POSITIVE HOME-CoV rule; Table S2: 4C Mortality Score composition, adapted from Knight S.R. et al.; Table S3: Cross-tabulation of LUS data and 30-day clinical outcomes; Table S4: Cross-tabulation of HOME-CoV/4CMS classification and 30-day clinical outcomes; Figure S1: Calibration plots of LUS for (A) the primary outcome and (B) secondary outcome; Figure S2: Overlap of HCR, 4CMS and LUS results in study patients. (A) Venn’s diagram. (B) Clinical and LUS classification. Green: low-risk (4CMS 0-3); yellow: intermediate-risk (4CMS 4-8); red: high-risk (4CMS ≥9).
Author Contributions: F.M. conceived the study; P.B., D.B., J.D.G., F.R., M.V., M.C. and G.D.S. collected the data; E.F., G.L., F.A., S.P., P.N. and E.L. supervised data collection; F.M. and P.B. analyzed the data and drafted the manuscript; E.P. provided statistical advice; E.P. and E.L. contributed substantially to its revision; F.M. takes responsibility for the paper as a whole. All authors have read and agreed to the published version of the manuscript.

Funding: The publication cost was covered by the Department of Medical Sciences, University of Turin.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of A.O.U. Città della Salute e della Scienza di Torino, A.O. Ordine Mauriziano, A.S.L. Città di Torino (0031189/24 March 2020 and 0009810/29 January 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available upon reasonable request.

Acknowledgments: We would like to thank all the ED personnel involved in patient management.

Conflicts of Interest: All authors state the absence of any potential financial and personal relationships with other people or organizations, even unrelated to the present study.

Abbreviations

4CMS: 4C mortality score; ED: emergency department; LUS: lung ultrasound.

References

1. Leira, E.C.; Russman, A.N.; Biller, J.; Brown, D.L.; Bushnell, C.D.; Caso, V.; Chamorro, A.; Creutzfeldt, C.J.; Cruz-Flores, S.; Elkind, M.S.V.; et al. Preserving stroke care during the COVID-19 pandemic: Potential issues and solutions. Neurology 2020, 95, 124–133. [CrossRef] [PubMed]
2. Kutikov, A.; Weinberg, D.S.; Edelman, M.J.; Horwitz, E.M.; Uzzo, R.G.; Fisher, R.I. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann. Intern. Med. 2020, 172, 756–758. [CrossRef] [PubMed]
3. Lucero, A.; Sokol, K.; Hyun, J.; Pan, L.; Labha, J.; Donn, E.; Kahwaji, C.; Miller, G. Worsening of emergency department length of stay during the COVID-19 pandemic. J. Am. Coll. Emerg. Physicians Open 2021, 2, e12489. [CrossRef] [PubMed]
4. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available online: https://www.covid19treatmentguidelines.nih.gov/ (accessed on 10 December 2021).
5. Lim, W.S.; van der Eerden, M.M.; Laing, R.; Boersma, W.G.; Karalus, N.; Town, G.I.; Lewis, S.A.; Macfarlane, J.T. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003, 58, 377–382. [CrossRef]
6. Fine, M.J.; Auble, T.E.; Yealy, D.M.; Hanusa, B.H.; Weissfeld, L.A.; Singer, D.E.; Coley, C.M.; Marrie, T.J.; Kapoor, W.N. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J. Med. 1997, 336, 243–250. [CrossRef]
7. Douillet, D.; Penaloza, A.; Mahieu, R.; Morin, F.; Chauvin, A.; Gennai, S.; Schotte, T.; Montassier, E.; Thiebaud, P.C.; Ghysen, A.; et al. Outpatient Management of Patients With COVID-19: Multicenter Prospective Validation of the Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection Rule to Discharge Patients Safely. Chest 2021, 160, 1222–1231. [CrossRef]
8. Knight, S.R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T.M.; Dunning, J.; Fairfield, C.J.; Gamble, C.; Green, C.A.; et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. Bmj 2020, 370, m3339. [CrossRef]
9. Haimovich, A.D.; Ravindra, N.G.; Stoytchev, S.; Young, H.P.; Wilson, F.P.; van Dijk, D.; Schulz, W.L.; Taylor, R.A. Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. Ann. Emerg. Med. 2020, 76, 442–453. [CrossRef]
10. Goodacre, S.; Thomas, B.; Sutton, L.; Burnsall, M.; Lee, E.; Bradburn, M.; Loban, A.; Waterhouse, S.; Simmonds, R.; Biggs, K.; et al. Derivation and validation of a clinical severity score for acutely ill adults with suspected COVID-19: The PRIEST observational cohort study. PLoS ONE 2021, 16, e0245840. [CrossRef]
11. Morello, F.; Bima, P.; Giamello, J.D.; Baricocchi, D.; Risi, F.; Vesan, M.; Pivetta, E.E.; Chiarolo, M.; Veglia, S.; Schivazappa, G.; et al. A 4C mortality score based dichotomic rule supports Emergency Department discharge of COVID-19 patients. Minerva Med. 2022, Online ahead of print. [CrossRef]
12. Pivetta, E.; Goffi, A.; Tizzani, M.; Locatelli, S.M.; Morrino, G.; Losano, I.; Leone, D.; Calzolari, G.; Vesan, M.; Steri, F.; et al. Lung Ultrasonography for the Diagnosis of SARS-CoV-2 Pneumonia in the Emergency Department. Ann. Emerg. Med. 2021, 77, 385–394. [CrossRef]
13. Volpicelli, G.; Gargani, L.; Perlini, S.; Spinelli, S.; Barbieri, G.; Lanotte, A.; Casasola, G.G.; Nogue-Bou, R.; Lamorte, A.; Agricola, E.; et al. Lung ultrasound for the early diagnosis of COVID-19 pneumonia: An international multicenter study. *Intensive Care Med.* 2021, 47, 444–454. [CrossRef]

14. Di Gioia, C.C.; Artusi, N.; Zotta, G.; Bonsano, M.; Sisto, U.G.; Tecchiolli, M.; Orso, D.; Cominotto, F.; Amore, G.; Meduri, S.; et al. Lung ultrasound in ruling out COVID-19 pneumonia in the ED: A multicentre prospective sensitivity study. *Emerg. Med. J.* 2021, 39, 199–205. [CrossRef] [PubMed]

15. Lichter, Y.; Topilsky, Y.; Taieb, P.; Banai, A.; Hochstadt, A.; Merdler, I.; Gal Oz, A.; Vine, J.; Goren, O.; Cohen, B.; et al. Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. *Intensive Care Med.* 2020, 46, 1873–1883. [CrossRef] [PubMed]

16. Ji, L.; Cao, C.; Gao, Y.; Zhang, W.; Xie, Y.; Duan, Y.; Kong, S.; You, M.; Ma, R.; Jiang, L.; et al. Prognostic value of bedside lung ultrasound score in patients with COVID-19. *Crit. Care* 2020, 24, 700. [CrossRef] [PubMed]

17. Trias-Sabrià, P.; Molina-Molina, M.; Aso, S.; Argudo, M.H.; Diez-Ferrer, M.; Sabater, J.; Dorca, J.; Santos, S.; Suarez-Cuartin, G. Lung Ultrasound Score to Predict Outcomes in COVID-19. *Respir. Care* 2021, 66, 1263–1270. [CrossRef]

18. Alexander, S.; Bonthu, M.; Calaway, N.; Cornwell, A.; Davis, J.; Elmes, P.; King, S.; Krushinskie, A.; Masters, A.; McKenzie, D.; et al. ACEP COVID-19 Field Guide; American College of Emergency Physicians: Irving, TX, USA, 2021.

19. Soummer, A.; Perbet, S.; Brisson, H.; Arbelot, C.; Constantin, J.M.; Lu, Q.; Rouby, J.J. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress*. *Crit Care Med.* 2012, 40, 2064–2072. [CrossRef]

20. Bitar, Z.I.; Shamsah, M.; Maadarani, O.; Bamasood, O.M.; Bitar, A.Z.; Alfoudri, H. Lung Ultrasound and Sonographic Subpleural Consolidation in COVID-19 Pneumonia Correlate with Disease Severity. *Crit. Care Res. Pract.* 2021, 2021, 6695033. [CrossRef]

21. Mandrekar, J.N. Receiver operating characteristic curve in diagnostic test assessment. *J. Thorac. Oncol.* 2010, 5, 1315–1316. [CrossRef]

22. Greiner, M. Two-graph receiver operating characteristic (TG-ROC): Update version supports optimisation of cut-off values that minimise overall misclassification costs. *J. Immunol Methods* 1996, 191, 93–94. [CrossRef]

23. Zhou, X.; Obuchowski, N.; McClish, D. *Statistical Methods in Diagnostic Medicine*, 2nd ed.; Sons, J.W., Ed.; Wiley: Hoboken, NJ, USA, 2011.

24. Derrick, B.; Dobson-Mckittrick, A.; Toher, D.; White, P. Test statistics for comparing two proportions with partially overlapping samples. *J. Appl. Quant. Methods* 2015, 10, 1–14.

25. Steyerberg, E.W.; Vickers, A.J.; Cook, N.R.; Gerds, T.; Gonen, M.; Obuchowski, N.; Pencina, M.J.; Kattan, M.W. Assessing the performance of prediction models: A framework for traditional and novel measures. *Epidemiology* 2010, 21, 128–138. [CrossRef] [PubMed]

26. Cox, D.R. Two further applications of a model for binary regression. *Biometrika* 1958, 45, 562–565. [CrossRef]

27. Kilaru, A.S.; Lee, K.; Snider, C.K.; Meisel, Z.F.; Asch, D.A.; Mitra, N.; Delgado, M.K. Return Hospital Admissions Among 1419 COVID-19 Patients Discharged from Five U.S. Emergency Departments. *Acad. Emerg. Med.* 2020, 27, 1039–1042. [CrossRef] [PubMed]

28. See, K.C.; Ong, V.; Wong, S.H.; Leanda, R.; Santos, J.; Taculod, J.; Phua, J.; Teoh, C.M. Lung ultrasound training: Curriculum implementation and learning trajectory among respiratory therapists. *Intensive Care Med.* 2016, 42, 63–71. [CrossRef]

29. Mojoli, F.; Bouhemad, B.; Mongodi, S.; Lichtenstein, D. Lung Ultrasound for Critically Ill Patients. *Am. J. Respir. Crit. Care Med.* 2019, 199, 701–714. [CrossRef]